305 related articles for article (PubMed ID: 24420749)
1. Molecular aspects of cholangiocarcinoma.
Kiguchi K
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
[TBL] [Abstract][Full Text] [Related]
2. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
[No Abstract] [Full Text] [Related]
3. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
6. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
9. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
[TBL] [Abstract][Full Text] [Related]
10. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
12. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
13. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
[TBL] [Abstract][Full Text] [Related]
14. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
17. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
Jensen LH; Jakobsen A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma.
Krasinskas AM
Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
Law LY
J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
[No Abstract] [Full Text] [Related]
20. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Sirica AE
World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]